FDA Approves Less Frequent Lebrikizumab Dosing - Top-Institutions - MDSpire

FDA Approves Less Frequent Lebrikizumab Dosing

Approval adds an every-8-week maintenance option for eligible patients with moderate-to-severe atopic dermatitis.

  • By

  • Kathryn Wighton

  • June 10, 2026

  • 2 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Northwestern University
    Northwestern University

    Chicago, Illinois

    Key Differentiators

    • Dermatology

  • #2

    City of Hope
    City of Hope

    Duarte, California

    Key Differentiators

    • Dermatology

  • #3

    Retina Consultants of Texas
    Retina Consultants of Texas

    Dallas, Texas

    Key Differentiators

    • Ophthalmology

  • #4

    Michigan Retina Center
    Michigan Retina Center

    Ann Arbor, Michigan

    Key Differentiators

    • Ophthalmology

  • #5

    Duke University
    Duke University

    Durham, North Carolina

    Key Differentiators

    • Dermatology

Original Source(s)

FDA Approves Less Frequent Lebrikizumab Dosing

  • by Kathryn Wighton

  • June 10, 2026

Related Content

From Sophie Spitz to Molecular Melanocytoma

How one woman's pioneering research transformed pediatric melanoma diagnosis

Studies on allergic diseases and B cells in the past 20 years: a bibliometric analysis via CiteSpace and VOSviewer

Symposium on Hidradenitis Suppurativa Advances 2025 Proceedings